- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Lexeo Therapeutics raises $153.8 million in public offering | 2 | Investing.com | ||
| Mo | Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters' Option to Purchase Additional Shares in the Public Offering | 1 | GlobeNewswire (USA) | ||
| 17.10. | Lexeo Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.10. | Stifel lowers Lexeo Therapeutics stock price target to $18 on offering | 5 | Investing.com | ||
| 17.10. | Lexeo Therapeutics Announces FDA Support for Accelerated Approval Pathway, Positive Interim Data for Gene Therapy LX2006 | 4 | Insider Monkey | ||
| 17.10. | Lexeo Therapeutics prices $135M public offering and private placement | 2 | Seeking Alpha | ||
| 17.10. | Lexeo Therapeutics platziert Aktien und Optionsscheine im Wert von 135 Millionen US-Dollar | 1 | Investing.com Deutsch | ||
| 17.10. | Lexeo Therapeutics prices $135 million public offering and placement | 2 | Investing.com | ||
| LEXEO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 17.10. | Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement | 1 | GlobeNewswire (USA) | ||
| 16.10. | Lexeo Therapeutics launches stock and warrant offering | 1 | Seeking Alpha | ||
| 16.10. | Lexeo Therapeutics announces public offering and private placement | 1 | Investing.com | ||
| 16.10. | Lexeo Therapeutics stock falls after announcing public offering | 1 | Investing.com | ||
| 16.10. | Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants | 1 | GlobeNewswire (USA) | ||
| 08.10. | H.C. Wainwright raises Lexeo Therapeutics stock price target to $15 on FDA feedback | 1 | Investing.com | ||
| 07.10. | Lexeo says FDA open to speedier approval of rare disease gene therapy | 3 | BioPharma Dive | ||
| 07.10. | Lexeo Therapeutics stock soars after FDA accelerated approval progress | 3 | Investing.com | ||
| 07.10. | Lexeo climbs after regulatory update on Friedreich ataxia drug | 2 | Seeking Alpha | ||
| 07.10. | Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy | 155 | GlobeNewswire (Europe) | U.S. Food and Drug Administration (FDA) open to pooling data from ongoing Phase I/II studies of LX2006 with pivotal data to support a Biologics License Application (BLA) for Accelerated Approval Interim... ► Artikel lesen | |
| 07.10. | Lexeo Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 15.08. | Lexeo Therapeutics stock price target lowered to $9 at H.C. Wainwright | 1 | Investing.com |
1 2 3 Weiter >>
56 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANGAMO THERAPEUTICS | 0,560 | +2,85 % | Sangamo Therapeutics: Die Chance ist noch nicht vom Tisch! | ||
| T2 BIOSYSTEMS | 0,250 | 0,00 % | NSE/A - T2 Biosystems, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| AVID BIOSERVICES | 12,100 | 0,00 % | Avid Bioservices Appoints Kenneth Bilenberg as CEO | ||
| PROTALIX BIOTHERAPEUTICS | 1,860 | -7,92 % | Why Is Protalix BioTherapeutics Stock Falling On Friday? | ||
| REPLIMUNE | 7,650 | +1,32 % | Replimune, Inc.: Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma | WOBURN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced... ► Artikel lesen | |
| ENZO BIOCHEM | 0,388 | 0,00 % | Battery Ventures Completes Take-Private of Enzo Biochem | Apter joins as CEO to support the next stage of growth for the life-science reagents platform
BOSTON--(BUSINESS WIRE)--Battery Ventures, a global, technology-focused investment firm, announced the... ► Artikel lesen | |
| QUANTERIX | 5,720 | -2,47 % | Quanterix Corporation Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the Blood and Tissue Continuum | BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced... ► Artikel lesen | |
| BELITE BIO | 78,00 | 0,00 % | Belite Bio stock rating reiterated at Buy by H.C. Wainwright | ||
| QIAGEN | 42,405 | +0,32 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| EVOTEC | 6,972 | +1,54 % | Übernahme von Vidac Pharma und Evotec? 400 Mrd. USD bei Pfizer, Merck und Co im Feuer! | Alarm bei Big Pharma! Donald Trump scheint bei der Reduzierung von Medikamentenpreisen ernst zu machen. Gleichzeitig laufen Patente bei Blockbustern aus und ein 400 Mrd. USD Umsatzausfall droht. Pfizer... ► Artikel lesen | |
| NEUPHORIA THERAPEUTICS | 6,260 | +55,34 % | Morning Market Movers: AlphaVest Acquisition Corp., Neuphoria Therapeutics, BranchOut Food, rYojbaba See Big Swings | BEIJING (dpa-AFX) - At 7:35 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| BIONTECH | 90,95 | +0,17 % | Summit Therapeutics: Daten überzeugen - BioNTech beobachten! | Am morgigen Dienstag neigt sich die Jahrestagung der European Society for Medical Oncology (ESMO) in Berlin schon wieder dem Ende entgegen. Zahlreiche Unternehmen haben bereits am Wochenende frische... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 57,29 | +102,01 % | Morning Market Movers: Picard Medical, Qualigen Therapeutics, Inhibrx Biosciences, MidWestOne Financial GroupSee Big Swings | BEIJING (dpa-AFX) - At 7:45 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,040 | +5,59 % | Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings | ||
| BB BIOTECH | 43,150 | +4,48 % | BB Biotech profitiert von Erfolgen im Portfolio | Schaffhausen - Die Beteiligungsgesellschaft BB Biotech hat im dritten Quartal mit 448 Millionen Franken einen hohen Gewinn erzielt, nach Verlusten in den beiden Quartalen davor. Nebst einem verbesserten... ► Artikel lesen |
Das Unternehmen LEXEO THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,56 % bei einem Aktienkurs von 9,230 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LEXEO THERAPEUTICS INC finden Sie auf Wallstreet Online.